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Summary
Diabetes causes pancreatic β cell failure through hyperglycemia-induced oxidative stress, or “glucose toxicity.” We show
that the forkhead protein FoxO1 protects β cells against oxidative stress by forming a complex with the promyelocytic
leukemia protein Pml and the NAD-dependent deacetylase Sirt1 to activate expression of NeuroD and MafA, two Insulin2
(Ins2) gene transcription factors. Using acetylation-defective and acetylation-mimicking mutants, we demonstrate that
acetylation targets FoxO1 to Pml and prevents ubiquitin-dependent degradation. We show that hyperglycemia suppresses
MafA expression in vivo and that MafA inhibition can be prevented by transgenic expression of constitutively nuclear
FoxO1 in β cells. The findings provide a mechanism linking glucose- and growth factor receptor-activated pathways to
protect β cells against oxidative damage via FoxO proteins.Introduction
Forkhead transcription factors of the FoxO subfamily play
important roles in cellular differentiation, proliferation, and me-
tabolism. Because of their pivotal role in diverse cellular pro-
cesses, there exist complex mechanisms to regulate FoxO-
dependent transcription (Accili and Arden, 2004). Hormones
and growth factors inhibit FoxO via phosphorylation by a host
of serine-threonine kinases (Kops and Burgering, 1999). In con-
trast, oxidative stress leads to changes of the acetylation
status of FoxO proteins. Evidence from overexpression studies
indicates that FoxO is acetylated by the nuclear receptor co-
activators Cbp and p300 and deacetylated by histone deacety-
lases (HDACs) and NAD-dependent deacetylases (Brunet et
al., 2004; Daitoku et al., 2004; Motta et al., 2004; van der Horst
et al., 2004).
An important target tissue of FoxO signaling is the pancreatic
β cell. This cell is the archetypal metabolic sensor, as it adjusts
insulin secretion to prevailing glucose levels. Failure of β cell
function is commonly seen in type 2 diabetes, but the nature
of the underlying metabolic abnormality is unclear (Bell and
Polonsky, 2001). A widely held theory is that chronic exposure
to elevated glucose concentrations causes a deterioration of β
cell function (“glucose toxicity”). Glucose toxicity is thought to
arise as a consequence of chronic oxidative stress, when intra-
cellular glucose concentrations exceed the glycolytic capacity
of the β cell. Under these conditions, glucose is shunted to
enolization pathways, leading to superoxide formation (Robert-
son et al., 2003). β cells are ill equipped to dispose of hydroxyl
radicals, as their complement of antioxidant enzymes, such as
catalase, Mn-superoxide dismutase (Mn-SOD), and glutathione
peroxidase, is low (Lenzen et al., 1996; Welsh et al., 1995). ItCELL METABOLISM : SEPTEMBER 2005 · VOL. 2 · COPYRIGHT © 2005has been proposed that an increase in hydroxyl radicals im-
pairs expression of the Ins2 gene transcription factor Pdx1
(Poitout et al., 1996; Sharma et al., 1995). This leads, in turn,
to decreased Ins2 gene transcription and increased apoptosis.
We have previously shown that FoxO1 haploinsufficiency re-
stores β cell mass and prevents diabetes in Insulin receptor
substrate 2 (Irs2) knockout mice(Kitamura et al., 2002). We
have also shown that overexpression of constitutively nuclear
FoxO1 in β cells prevents compensatory β cell hyperplasia in
insulin-resistant mice (Nakae et al., 2002). These data provide
evidence that FoxO1 regulates β cell mass, but it remains un-
clear whether it also regulates β cell function.
In this study, we have uncovered a new role of FoxO1 in
the protection against β cell failure. Exposure of βTC-3 cells to
hydrogen peroxide, an inducer of superoxide formation, targets
FoxO1 to Pml-containing nuclear subdomains and increases
expression of the Ins2 gene transcription factors NeuroD and
MafA in a FoxO1-dependent manner. Acetylation is required to
target FoxO1 to nuclear Pml bodies, while deacetylation by the
NAD-dependent deacetylase Sirt1 is required to induce gene
expression. Using acetylation-defective and “constitutively
acetylated” FoxO mutants, we show that acetylation affects
the balance between protein stability and DNA transcription.
Thus, acetylation-defective mutants are more transcriptionally
active than wild-type (wt) FoxO1 but are more rapidly ubiq-
uitinated and degraded, while mutations that mimic the acet-
ylated state increase stability but impair FoxO1 transcription.
Consistent with the idea that FoxO1 plays a role in the regula-
tion of MafA expression in vivo, we show that FoxO1 and MafA
levels are concordantly decreased in diabetic animals. Expres-
sion of a constitutively nuclear FoxO1 transgene in β cells pre-
vents MafA downregulation in response to hyperglycemia.ELSEVIER INC. DOI 10.1016/j.cmet.2005.08.004 153
A R T I C L EThese data indicate that FoxO1 orchestrates a compensatory
response, aimed at preserving β cell function under conditions
of metabolic stress.
Results
Nuclear translocation of FoxO1 in response
to oxidative stress
In most cell types, FoxO1 shuttles between nucleus and cyto-
plasm. Cultured pancreatic βTC-3 cells behave unlike other cell
types, as in these cells FoxO1 is constitutively cytoplasmic,
presumably reflecting tonic activation of insulin receptor signal-
ing by endogenously produced insulin (Harbeck et al., 1996).
Thus, endogenous FoxO1 is constitutively phosphorylated at
the main phosphorylation sites, S253 and S316, (Figure 1A)
and localizes to the cytoplasm in cultured βTC-3 cells (Figure
1B). We asked whether metabolic challenges affect FoxO1 lo-
calization. However, removal of serum and/or glucose from the
medium for up to 72 hr did not affect FoxO1 localization or
phosphorylation (Figures 1A and 1B). In contrast, incubation of
β cells with H2O2 for up to 24 hr to induce oxidative stress
resulted in nuclear redistribution of FoxO1 in w30% of cells
(Figure 1C and Table 1). To demonstrate the physiological rele-
vance of this observation, we determined FoxO1 subcellular
localization in primary islet cell cultures, which are composed
by >90% of β cells (data not shown). As in βTC-3 cells, endog-
enous FoxO1 is cytoplasmic in primary β cells. H2O2 promoted
Foxo translocation in w45% of primary islet cells and culture
in 25 mM glucose in w20% of cells (Figure 1D and Table 1).
Thus, H2O2 treatment of βTC-3 cells faithfully recapitulates the
effects of hyperglycemia in β cells.
Exposure to oxidative stress during the S phase of the cell
cycle results in apoptosis (Chen et al., 2000). Conversely, ex-
posure to oxidative stress in the G1 or G2/M phase leads to
“stress-induced premature senescence” (Frippiat et al., 2001),
presumably to prevent somatic mutations induced by DNA
damage. Following treatment with H2O2, we observed a sharp
increase in the number β cells undergoing premature senes-
cence in primary islet cell cultures. The increase in cellular se-
nescence was mimicked by constitutively nuclear FoxO1 and
was partially blunted by dominant-negative FoxO1 (Figures 1E
and 1F), consistent with the idea that FoxO1 nuclear transloca-
tion promotes cellular survival under stress.
FoxO1 induces NeuroD expression in response to H2O2
To evaluate the functional consequences of FoxO1 redistribu-
tion, we measured expression of the Ins2 gene transcription
factor NeuroD in βTC-3 cells exposed to H2O2. This protein is
expressed in uncommitted pancreatic endocrine precursor
cells and then becomes restricted to differentiated β cells, where
it promotes Ins2 expression (Jensen et al., 2000; Schwitzgebel et
al., 2000). NeuroD knockout mice develop diabetes shortly after
birth, due to a >70% decrease in endocrine cell number (Miy-
ata et al., 1999; Naya et al., 1997). In cultured βTC-3 cells, we
found only occasional NeuroD-positive cells, consistent with
the observation that NeuroD is not absolutely required for β
cell function and Ins2 gene transcription (Huang et al., 2002).
Following H2O2 treatment, most βTC-3 cells that scored posi-
tive for nuclear FoxO1 also demonstrated NeuroD expression
(Figure 2A). A similar induction of NeuroD expression could be
brought about by overexpression of constitutively nuclear154ADA-FoxO1 (Figures 2B and 2C). We observed a similar in-
crease of NeuroD mRNA in primary islet cultures exposed to
H2O2 or 25 mM glucose (Figure S1 available with this article
online). During embryonic endocrine cell differentiation, activa-
tion of NeuroD is associated with growth arrest (Jensen et al.,
2000). However, in cultured βTC-3 cells, we found that 97% of
the scarce NeuroD-positive cells are Ki67 positive, indicating
that they are actively replicating (Figure 2D). In contrast, follow-
ing H2O2 treatment, only 5.7% of FoxO1/NeuroD-positive cells
were Ki67 positive, while the remainder (>94%) were Ki67
negative, indicating that they are growth arrested. As growth
arrest is an important FoxO function (Medema et al., 2000), this
experiment provides further evidence for activation of the FoxO
transcriptional program.
To distinguish between direct and indirect effects of FoxO1
on NeuroD transcription, we performed gel shift, promoter ac-
tivity, and chromatin immunoprecipitation (ChIP) assays. Incu-
bation of nuclear extracts from βTC-3 cells with a labeled oli-
gonucleotide spanning five forkhead sites in the NeuroD
promoter gave rise to a gel-retarded band that could be speci-
fically supershifted by FoxO1 antiserum (Figure 2E). Moreover,
expression of ADA-FoxO1 resulted in a 6-fold induction of
NeuroD promoter activity, which was abolished by point muta-
tions of the FoxO1 consensus sites (Figure 2F). ChIP assays
demonstrated that FoxO1 binds to a forkhead site of the Neu-
roD promoter in intact chromatin in an H2O2-dependent man-
ner (Figure 2G).
FoxO1 promotes MafA expression
MafA is an Ins2 gene transcription factor that is expressed at
the beginning of the “secondary transition” in β cells. The onset
of MafA expression coincides with β cell acquisition of glucose
competence, i.e., the ability to respond to changes in glucose
concentrations with insulin secretion (Matsuoka et al., 2004;
Olbrot et al., 2002). Similar to the findings for NeuroD expres-
sion, we detected increased MafA levels in response to H2O2
treatment or ADA-FoxO1 transduction (Figure 3A). Similarly,
H2O2 or 25 mM glucose treatment increased MafA levels in
primary islets (Figure S1). Coexpression of FoxO1 with a repor-
ter gene driven by the MafA promoter increased luciferase ac-
tivity w20-fold compared to control vector in transient trans-
fection studies (Figure 3B), and ChIP assays showed that
FoxO1 binds to a forkhead element in the MafA promoter in an
H2O2-dependent manner (Figure 3C). These data indicate that
MafA is a direct FoxO target.
Prolonged culture of β cells with high glucose decreases
MafA binding to the Ins2 promoter (Poitout et al., 1996), but
there is no information on MafA protein levels in diabetes. We
analyzed MafA immunoreactivity in pancreas sections from mice
with a range of different glucose levels. In wt mice, virtually all
β cells expressed MafA, as did β cells of mice with hypoglyce-
mia (Insr 80)(Kitamura et al., 2004) (Figure 3D). In contrast,
we observed a decrease in MafA expression in two models of
diabetes, one with mild hyperglycemia (w150 mg/dl) caused
by overexpression of constitutively nuclear FoxO1 in liver
(FoxO307, Figure 3D) (Nakae et al., 2002) and one with marked
hyperglycemia (>400 mg/dl) caused by insulin receptor muta-
tions (L2, Figure 3C) (Okamoto et al., 2004). These findings in-
dicate that MafA expression is exquisitely sensitive to in-
creases in plasma glucose levels.
We then asked whether constitutive nuclear expression ofCELL METABOLISM : SEPTEMBER 2005
FoxO1 in β cell failureFigure 1. FoxO1 translocates to the nucleus in re-
sponse to H2O2
A) We analyzed FoxO1 phosphorylation by Western
blotting with antisera against phospho-Ser256, pho-
spho-Ser316, and anti-FoxO1.
B) Immunocytochemical analysis of FoxO1 distribu-
tion in βTC-3 cells following serum or glucose de-
pletion.
C) We treated βTC-3 cells with or without 50 M
H2O2 for 12 hr, then performed immunocytochemis-
try to determine FoxO1 distribution. Arrows indicate
cells with nuclear FoxO1.
D) We isolated islets (consisting of >90% β cells)
and cultured them in the presence or absence of
25 mM glucose or 50 M H2O2 for 24 hr prior to
performing immunocytochemistry as indicated
above to detect endogenous FoxO1.
E) We cultured primary islets in the presence or ab-
sence of 50 M H2O2 for 7 days or transduced them
with FoxO1-ADA, FoxO1-DN (256), or GFP adeno-
virus at a MOI of 1 and then continued culture for
the same length of time. At the end of the experi-
ment, we measured senescence by SA β-galactosi-
dase activity assays to visualize lysosomes.
F) We counted the number of SA β-galactosidase-
positive cells in more than 20 islet cell clusters. We
present the data as the mean percentage of SA
β-galactosidase-positive cells (±SEM). An asterisk
indicates p < 0.05 by one factor-ANOVA.FoxO1 in β cells could prevent MafA downregulation by hyper-
glycemia. We analyzed mice expressing a constitutively
nuclear FoxO1 transgene in both liver and β cells (FoxO305)
(Nakae et al., 2002). Despite similar plasma glucose levels to
FoxO307 mice (w150 mg/dl), FoxO305 mice retained normalCELL METABOLISM : SEPTEMBER 2005MafA expression by immunohistochemistry (Figure 3D) and
mRNA levels (Figure S2). To examine this point further, the
same FoxO305 mice were rendered more severely diabetic by
intercrossing them with insulin-resistant mice (L1, Figure 3C)
(Okamoto et al., 2004). The resulting mice had glucose levels155
A R T I C L ETable 1. FoxO1 nuclear translocation in response to oxidative stress
Nuclear/
Condition Nuclear Cytoplasmic Cytoplasmic
βTC-3 basal 0 0 100
βTC-3 H2O2 24 ± 5 5 ± 2 70 ± 5
Primary islets basal 0 0 100
Primary islets H2O2 30 ± 5 15 ± 3 55 ± 4
Primary islets 25 mM 10 ± 2 8 ± 3 80 ± 5
glucose
Quantification of the effects of H2O2 and hyperglycemia on FoxO1 subcellular
localization. We quantitated the number of cells with nuclear, cytoplasmic, and
combined nuclear/cytoplasmic patterns of FoxO1 expression. Values are ex-
pressed as percentage of all scored cells. Each experiment was conducted at
least three times.w400 mg/dl (H. Okamoto and D.A., unpublished data). MafA
expression was preserved in 70% of β cells, as opposed to
10% of β cells in diabetic mice with similar glucose levels (L2,
Figure 3D). If FoxO1 is required to induce MafA in vivo and
MafA is reduced in diabetes, the expectation would be that
FoxO1 levels should also be decreased in diabetic animals. As
shown in Figure 3E, we observed a profound decrease in
FoxO1 expression in two models of adult-onset type 2 diabe-
tes, one caused by β cell dysfunction (Irs2−/−)(Withers et al.,
1998) and one caused by insulin resistance (L2) (Okamoto et
al., 2004). These data are consistent with the hypothesis that
FoxO1 participates in the regulation of MafA expression in vivo.
FoxO1 is targeted to Pml bodies
The observations that oxidative damage increases expression
of FoxO1 target genes, while FoxO1 levels are decreased in
diabetes, are apparently at odds. To reconcile them, we hy-
pothesized that, as FoxO1 is retained in the nucleus, it is also
more rapidly degraded. If so, nuclear retention in response to
oxidative stress would only afford a temporary reprieve against
the metabolic onslaught of chronic hyperglycemia. The next
set of experiments was designed to uncover the posttransla-
tional modifications that determine the balance between
FoxO1-dependent transcription and protein stability.
Oxidative stress causes extensive posttranslation protein
modifications, including acetylation and ubiquitination (Brooks
and Gu, 2003). As shown in several studies (Brunet et al., 2004;
Daitoku et al., 2004; Motta et al., 2004; van der Horst et al.,
2004), FoxO1 was transiently acetylated in response to H2O2
treatment. In vivo coimmunoprecipitation studies and in vitro
assays with purified FoxO1-GST indicate that FoxO1 is acet-
ylated by the nuclear coactivators Cbp/p300 and deacetylated
by the NAD-dependent deacetylase (Sirtuin) Sirt1 (Figure S3).
It has been suggested that acetylation promotes FoxO-depen-
dent transcription (Daitoku et al., 2004; Motta et al., 2004).
However, this point remains controversial, with some data sug-
gesting that acetylation increases (Motta et al., 2004), and oth-
ers that it decreases FoxO activity (Brunet et al., 2004; Daitoku
et al., 2004; van der Horst et al., 2004). We hypothesized that
acetylation is required to target FoxO to transcriptionally active
nuclear domains, rather than directly promote FoxO-depen-
dent transcription.
The promyelocytic leukemia-associated protein Pml forms
characteristic nuclear subdomains (Pml nuclear bodies), where156several transcriptional regulators reside (Guo et al., 2000; Pear-
son and Pelicci, 2001). Pml is also a mediator of stress-
induced premature senescence (Pearson and Pelicci, 2001).
Therefore, we investigated whether FoxO1 associates with Pml
during oxidative stress. We detected Pml in FoxO1 immuno-
precipitates following treatment with H2O2 (Figure 4A). Immu-
nohistochemical studies in βTC-3 cells indicated that these two
proteins are found in different cellular compartments in basal
conditions but colocalize in a punctate nuclear pattern follow-
ing H2O2 treatment (Figure 4B). These results indicate that
FoxO1 engages in protein-protein interactions with Pml in
response to oxidative stress. We next examined whether inhibi-
tion of FoxO1 or Pml by siRNA would affect NeuroD expres-
sion. The FoxO1 and Pml siRNAs effectively abolished expres-
sion of the two proteins (Figure 4C). Consistent with the
hypothesis that Pml and FoxO1 are required for NeuroD induc-
tion, we saw that NeuroD levels decreased in cells expressing
either siRNA (Figure 4C).
To determine whether acetylation is required for FoxO1 bind-
ing to Pml, we introduced mutations that affect FoxO1 acetyla-
tion. We replaced six lysine residues corresponding to pro-
posed FoxO acetylation sites (K242, K245, K259, K262, K271,
and K291) (Brunet et al., 2004; Daitoku et al., 2004) with argi-
nine to prevent acetylation (henceforth KR series), and with
glutamine to mimic it (Luo et al., 2004) (henceforth KQ series)
(Figure S4). To rule out the competing effects of nuclear exclu-
sion, we introduced the mutations both in wt and in a phos-
phorylation-defective mutant (ADA-FoxO1). However, the re-
sults are identical with both sets of constructs. Moreover,
neither the 6KR nor the 6KQ mutant showed alterations of
nuclear exclusion in response to insulin treatment (data not
shown). Consistent with the observation that acetylation is re-
quired to target FoxO1 to Pml, the 6KR mutant failed to bind
Pml in response to H2O2, while the 6KQ mutant was constitu-
tively bound to it even in the absence of H2O2 (Figure 4D). We
obtained similar data in Sirt1 coimmunoprecipitations (Figure
4E). In contrast, neither the 6KR nor the 6KQ mutant bound to
Cbp (Figure 4F). These data indicate that acetylation of these
residues is required for the interaction of FoxO1 with Pml and
Sirt1.
Pml targets FoxO1 for ubiquitin-mediated degradation
Acetylation affects protein degradation via ubiquitination (Ito et
al., 2002; Jeong et al., 2002; Li et al., 2002). Accordingly, we
observed that less FoxO1 was ubiquitinated in response to
H2O2 (Figures 5A and 5B) and that protein half-life was ex-
tended from w4 hr to >12 hr in cells treated with H2O2 or de-
acetylase inhibitors (Figure S5).
To determine whether acetylation affects ubiquitin-depen-
dent degradation, we determined the ubiquitination of the 6KR
and 6KQ mutants. Consistent with the idea that acetylation in-
hibits degradation via the ubiquitin pathway, we observed
decreased ubiquitination of the 6KQ mutant and increased
ubiquitination of the 6KR mutant (Figure 5C). Moreover, we ob-
served that FoxO1 ubiquitination increased in cells coexpress-
ing FoxO1 and Pml or Sirt1 and decreased in cells coexpress-
ing FoxO1 and Cbp (Figure 5D). Finally, we observed that
FoxO1 levels decreased in cells overexpressing Pml in a Pml-
dose-dependent manner (Figure 5E, left panel). This effect was
blocked by MG132 (Figure 5E, right panel), indicating that it
requires FoxO targeting to the proteosomal compartment.CELL METABOLISM : SEPTEMBER 2005
FoxO1 in β cell failureFigure 2. FoxO1 activates NeuroD expression
A) We treated βTC-3 cells with or without 50 M H2O2 for 24 hr, then performed immunostaining for FoxO1 (green) and NeuroD (red).
B) We transduced βTC-3 cells with HA-tagged FoxO1-ADA adenovirus and performed immunostaining with anti-HA antiserum (green) and NeuroD (red) following
treatment.
C) We determined expression of FoxO1 and NeuroD by Western blotting under the conditions indicated in (A).
D) Expression of NeuroD (red) and Ki67 (green) in βTC-3 cells following H2O2 treatment for 24 hr is shown.
E) FoxO1 binds to the NeuroD promoter in vitro. We incubated βTC-3 nuclear extracts with an oligonucleotide spanning five forkhead sites in the NeuroD promoter.
We performed electromobility gel shift assays in the presence of anti-FoxO1 antiserum or normal rabbit serum.
F) FoxO1 increased NeuroD promoter activity. We cotransfected βTC-3 cells with a wt 2.2 kb NeuroD promoter/pGL3 basic vector and ADA-FoxO1 (left panel) or a
mutant 2.2 kb promoter with point mutations of the forkhead binding sites (right panel). Bars indicate the mean fold-increase over basal values (+SEM).
G) ChIP assays of the NeuroD promoter are shown. We transduced βTC-3 cells with FoxO1 adenovirus and performed ChIP assays with the indicated antisera. The
crosslinked DNA was amplified by PCR using a set of primers spanning the forkhead binding sites in the NeuroD promoter. Input represents DNA extracted from
chromatin prior to immunoprecipitation.These data indicate that Pml or Sirt1 bound FoxO1 is more
rapidly ubiquitinated, suggesting that these interactions target
FoxO1 for degradation.
We finally asked whether changes in acetylation affect
FoxO1 transcription. We measured in vivo DNA binding usingCELL METABOLISM : SEPTEMBER 2005ChIP assays with the NeuroD promoter. In these experiments,
we used the constitutively nuclear FoxO-ADA mutant to rule
out the effects of nuclear translocation. We observed increased
binding of the 6KR mutant to the NeuroD promoter and de-
creased binding of the 6KQ mutant (Figure 5F). Moreover, the157
A R T I C L EFigure 3. FoxO1 promotes MafA expression in βTC-
3 cells and in transgenic mice
A) Western blot of FoxO1 and MafA in βTC-3 cells.
We treated βTC-3 cells with H2O2 for 24 hr or trans-
duced them with HA-tagged FoxO1-ADA as indi-
cated in Figure 2, and determined expression of
FoxO1 and MafA by Western blotting. To measure
nuclear FoxO1 levels, we isolated nuclei from βTC-
3 cells under the conditions indicated.
B) FoxO1 increased MafA promoter activity. We co-
transfected βTC-3 cells with a wt MafA promoter/
pGL3 basic vector and control vector or FoxO1,
then measured luciferase activity. Means ± SEM of
three experiments are shown.
C) FoxO1 is recruited to the MafA promoter. We in-
cubated βTC-3 cells in the absence or presence of
H2O2 (50 M) and performed ChIP assay with a
FoxO1 antiserum. For PCR, we used a set of prim-
ers corresponding to forkhead binding sites in the
MafA promoter.
D) We determined MafA expression in different mouse
models of diabetes. We prepared paraffin sections
from insulin receptor mosaic mice (Insr 80), wt,
FoxO1 transgenics (FoxO305 and FoxO307), insulin
receptor transgenic knockout (L2), or FoxO305 trans-
genics intercrossed with insulin receptor transgenic
knockouts (FoxO305::L1). We performed double
immunohistochemistry with MafA (red) and glucagon
(green).
E) FoxO expression in diabetic animals is shown.
We prepared paraffin sections from wt, Irs2−/−, and
insulin receptor transgenic knockout (L2) mice. We
performed double immunohistochemistry with
FoxO1 (red) and insulin (green).6KR mutant elicited stronger activity of a FoxO reporter gene
in luciferase assays than the 6KQ mutant (Figure 5G). Thus,
acetylation decreased and deacetylation increased FoxO1-
dependent gene expression.
Bimodal regulation of FoxO1 in response to H2O2
We summarize these data as a model in Figure 6. Under normal
conditions, FoxO1 is rapidly excluded from the nucleus in β158cells. In response to hyperglycemia (or H2O2), FoxO1 is acet-
ylated. Acetylation prevents ubiquitination—thus resulting in
acetyl-FoxO1 nuclear accumulation—and targets FoxO to Pml
bodies but hinders FoxO-dependent transcription. Upon asso-
ciating with the Pml body, FoxO is deacetylated by Sirt1, lead-
ing to increased transcription. However, the deacetylated pro-
tein is also more efficiently ubiquitinated. Thus, the tradeoff of
increased transcription is rapid degradation. The ostensibleCELL METABOLISM : SEPTEMBER 2005
FoxO1 in β cell failureFigure 4. FoxO1 binds to Pml in H2O2-treated
βTC-3 cells
A) FoxO1 binds to Pml following H2O2 treatment.
We cotransfected FLAG-Pml with HA-FoxO1-ADA
in βTC-3 cells. After treatment with H2O2 for 24 hr,
we immunoprecipitated cell extracts with FoxO1
(HA-tag antibody) and performed Western blotting
with anti-FLAG (Pml) (upper panel) or anti-FoxO1
antibody (middle panel), or we carried out immuno-
precipitation and Western blotting with anti-FLAG
antibody to normalize for Pml content (lower panel).
B) Endogenous FoxO1 colocalizes with Pml follow-
ing H2O2 treatment. Immunohistochemical analysis
of endogenous FoxO1 localization in βTC-3 cells ex-
posed to H2O2 for 24 hr is shown. To visualize Pml,
we transfected FLAG-tagged Pml.
C) FoxO1 and Pml inhibition by siRNA. Expression
of FoxO1 (left panel), Pml (middle panel), and Neu-
roD (right panel) in βTC-3 cells transfected with the
indicated siRNAs.
D) Acetylation-deficient FoxO1 (6KR) fails to bind to
Pml in response to H2O2, while acetylation-mimick-
ing mutant (6KQ) is constitutively bound to it in
βTC-3 cells.
E) Coimmunoprecipitation of mutant FoxO1 and
Sirt1. Similar to (D), acetylation-deficient FoxO1
fails to bind to Sirt1, while acetylation-mimicking
mutant is constitutively bound to it.
F) Interaction of FoxO1 with Cbp is prevented by
mutations affecting FoxO1 acetylation. We cotrans-
fected βTC-3 cells with FLAG-tagged FoxO1 and
HA-tagged Cbp and performed coimmunoprecipi-
tations as indicated.goal of this mechanism is to prevent unchecked FoxO-depen-
dent transcription, which has the potential to result in apopto-
sis (Brunet et al., 1999) or cellular atrophy (Sandri et al., 2004;
Stitt et al., 2004).
Discussion
The integration of metabolic signals, such as nutrients and glu-
cose—acting via oxidative stress—with growth factor/hor-
monal signals in the life cycle of the β cell has long bedeviled
the diabetes field. The main conclusion of these studies is that
these competing signals are integrated by FoxO1 to protect
against β cell failure.
A model of FoxO1 function in β cells
FoxO1 activates gene expression in response to oxidative
stress to preserve insulin secretion and promote cell survival.
Metabolic stress overrides phosphorylation-dependent nuclearCELL METABOLISM : SEPTEMBER 2005exclusion and causes nuclear retention via acetylation. The net
outcome is to increase expression of Ins2 gene transcription
factors (NeuroD and MafA), prevent β cell replication under
conditions that could eventuate in apoptosis, and promote β
cell senescence. Acetylation serves the twin purposes of
increasing FoxO1 stability and targeting FoxO1 to Pml nuclear
bodies, where it is deacetylated by Sirt1 to become transcrip-
tionally active. As unchecked FoxO1 transcription can be detri-
mental to the cell (Accili and Arden, 2004), deacetylated FoxO1
is rapidly degraded. Thus, FoxO1 translocation in response to
oxidative stress can be envisaged to allow β cells to withstand
acute metabolic changes, for example transient oscillations of
glucose levels. However, since deacetylated FoxO1 is de-
graded, this mechanism is unable to preserve β cell function in
the face of continuing stress, as indicated by the loss of FoxO1
expression in diabetic animals.
The present findings allow us to reconcile some unexplained
features of FoxO1 function in mature β cells and integrate them159
A R T I C L E160through FoxO1 (Poitout et al., 1996).
Figure 5. Mutations of acetylation sites affect FoxO1 ubiquitination and DNA
binding
A) FoxO1 is ubiquitinated in response to 50 m H2O2 treatment. βTC-3 cells
were incubated with the indicated concentrations of H2O2 for 24 hr, and FoxO1
was detected by blotting with anti-ubiquitin (Ubn) antiserum following FoxO1
immunoprecipitation.
B) To determine that the Ubn bound high-molecular-weight species was indeed
FoxO1 and not other proteins, we performed FoxO1 immunoblotting following
FoxO1 immunoprecipitation.
C) Ubiquitination of wt and acetylation site mutants of FoxO1 is shown. We co-
transfected βTC-3 cells with the FLAG-tagged FoxO1 constructs indicated at the
top of the panel and ubiquitin. Following immunoprecipitation with anti-FLAG
antiserum, we performed immunoblots with anti-ubiquitin antiserum. The lower
panel shows a control immunoblot with anti-FLAG antiserum to normalize protein
amount in each lane.
D) Ubiquitination of with-type FoxO1 in βTC-3 cells cotransfected with FLAG-
tagged FoxO1 and Pml, Sirt, or Cbp is shown.
E) Coexpression of FoxO1 and Pml results in increased proteasome-dependent
FoxO1 degradation. We compared FoxO1 protein levels in βTC-3 cells that had
been cotransfected with increasing amounts (5 or 10 g) of plasmid DNA encod-
ing Pml in the absence and presence of the proteasome inhibitor MG132 (25
m). We carried out MG132 treatment for 12 hr. Total DNA amount was kept
constant by adding vector DNA or GFP.
F) Acetylation-deficient FoxO1 mutant binds more avidly to the forkhead site of
the NeuroD promoter. We performed experiments as indicated in Figure 2, except
that we used 6KR and 6KQ FoxO1 mutants.
G) Reported promoter activity of acetylation site-mutant FoxO1s is shown. We
used a synthetic FoxO1 target sequence derived from the Igf binding protein-1
promoter to direct expression of a luciferase reporter gene. We carried out both
sets of experiments in βTC-3 cells. Bars indicate the mean fold-increase over
basal values (+SEM).into current models of diabetes pathophysiology (Accili, 2004).
We have previously shown that a constitutively nuclear FoxO1
impairs compensatory β cell hyperplasia in insulin-resistant
states but fails to impair β cell function, despite decreased
Pdx1 levels. While FoxO1 β cell transgenics are glucose intol-
erant at an early age and display mild hyperglycemia (120–150
mg/dl), they fail to become more severely diabetic with age
(Nakae et al., 2002). These seemingly irreconcilable effects can
now be explained by FoxO1’ s ability to promote MafA expres-
sion. Moreover, as in these transgenic mice FoxO1 expression
fails to be downregulated with the onset of hyperglycemia (be-
cause it is driven by a heterologous promoter), the mutant
FoxO1 becomes protective against further deterioration of β
cell function.
FoxO targets in the β cell
The identification of NeuroD as a FoxO1 target is noteworthy,
as thus far the only known NeuroD activator was Neurogenin3
(Huang et al., 2000), which, however, is not expressed in the
adult pancreas. Activation of NeuroD appears to recapitulate
an earlier differentiation stage of the β cell progenitor, when
cells turn on NeuroD expression and become mitotically ar-
rested (Jensen et al., 2000). The increase in MafA expression
in response to FoxO1 nuclear translocation should be viewed
as central to the β cell compensatory response, as hyperglyce-
mia has been shown to impair MafA-dependent Ins2 gene ex-
pression (Matsuoka et al., 2003). In this respect, we show that
MafA expression correlates with FoxO1 expression and de-
creases in genetic models of diabetes, providing a critical test
of the hypothesis that MafA expression is regulated by glucoseCELL METABOLISM : SEPTEMBER 2005
FoxO1 in β cell failureFigure 6. A model of FoxO1 function in β cells
FoxO1 nuclear retention protects β cells from oxidative stress-induced damage.
Acetylated FoxO is retained in the nucleus, where it engages Pml and Sirt1.
Deacetylation of FoxO1 by Sirt1 promotes FoxO1-dependent transcription and
accelerates FoxO1 degradation. Because FoxO becomes rapidly degraded when
deacetylated, this mechanism has the potential to protect β cells against acute
metabolic distress but not against the chronic changes associated with pro-
longed hyperglycemia, a common cause of oxidative stress that has been shown
to bring about β cell failure.The identification of Pml as a FoxO-interacting protein is
consistent with the role of Pml to regulate premature senes-
cence (Pearson and Pelicci, 2001), apoptosis (Quignon et al.,
1998), and targeting of transcriptional coactivators (Doucas et
al., 1999). We suggest that FoxO1 acetylation by p300/Cbp
and deacetylation by Sirt1 takes place within Pml bodies. Inter-
estingly, this model is opposite to the mechanism by which
deacetylation controls p53 function (Luo et al., 2001; Vaziri et
al., 2001). Our data raise the possibility that Pml regulates met-
abolic functions via interactions with FoxO proteins.
Conclusions
It will be important to investigate whether genetic or pharma-
cological manipulations of FoxO1 can be used to improve β
cell failure in diabetic patients, to preserve islet function prior to
transplant, or to drive differentiation of uncommitted endocrine
progenitors into β cells.
Experimental procedures
Antibodies
We purchased anti-insulin antibodies from Linco Research; anti-acetyl-
lysine, anti-Sirt1, and anti-acetylated histoneH3 antibodies from Upstate
Biotechnology; anti-FoxO1, anti-FoxO1 pSer256, and anti-FoxO1 pSer316CELL METABOLISM : SEPTEMBER 2005antibodies from Cell Signaling; anti-p300 (N-15), anti-CBP (C-20), anti-Neu-
roD (G-20 or N-19), anti-Pml (PG-M3), anti-FoxO1 (H-128), anti-Bad (C-7),
anti-c-Myc (9E10) and anti-ubiquitin (P4D1) antibodies from Santa-Cruz;
anti-HA (12CA5) antibody from Boehringer Mannheim; anti-glucagon and
anti-Flag (M2) antibodies from Sigma; anti-Ki67 antibody from Castra; anti-
Actin (Ab-1) antibody from Oncogene. For FoxO1 immunostaining, we used
a cocktail of three antisera from Cell signaling, Santa-Cruz, and the pre-
viously described antipeptide antiserum 3587 (Nakae et al., 2002).
Expression vectors and adenoviral vectors
We have previously described expression vectors encoding Myc-tagged
FoxO1, HA-tagged FoxO1-ADA (constitutively nuclear) and FoxO1-256
(dominant negative) (Nakae et al., 2002), FLAG-tagged p300 and Pml
(Zhong et al., 1999), HA-tagged Cbp (Gu et al., 1997), His-HA-ubiquitin (Li
et al., 2003), and adenoviral vectors encoding HA-tagged wt and FoxO1-
ADA (Nakae et al., 2001). We purchased the mouse Sirt1 expression vector
(Sir2α/pUSEamp) from Upstate Biotechnology. To generate the 4KR and
4KQ mutants, we replaced K242, K245, K259, and K262 with arginine or
glutamine. To generate the 6KR and 6KQ mutants, we replaced two addi-
tional lysine residues (K271 and K291) with arginine or glutamine. We car-
ried out site-directed mutagenesis using the Quick Change kit (Stratagene).
Cell culture, transfection, and viral transduction
We cultured βTC-3 cells in high glucose DMEM supplemented with 15%
horse serum and 2.5% FCS. In some experiments, we infected βTC-3 cells
with FoxO1 adenovirus 6 hr before treatments at MOIs between 1 and 30.
All experiments were repeated at least three times.
Immunoprecipitation and Western blotting
We lysed cultured cells in RIPA buffer containing 10 M TSA, 10 mM NAM,
and protease inhibitors (Roche). After centrifugation, cell extracts were di-
luted with Co-IP buffer (50 mM Tris, 150 mM NaCl, 0.1% NP-40, 10% glyc-
erol, 5 mM MgCl2), immunoprecipitated, and analyzed by immunoblotting.
Gel shift and luciferase assays
We performed gel shift assays as described previously (Kitamura et al.,
2002). We used the following oligonucleotide probe: GGTATTTAAACGCAA
CACCCAGAGTAAATGAAAAAAAACAAAAACAAAACAAAAAAACAA (−1831
to −1772 of the NeuroD promoter). In some experiments, we incubated anti-
FoxO1 or nonimmune sera with nuclear extracts for 1 hr prior to adding
radiolabeled probe into the reaction mixture. We performed luciferase as-
says as previously (Kitamura et al., 2002), using a wt 2.2 kb NeuroD pro-
moter fragment cloned into a pGL3 basic vector (Stratagene) or a mutant
promoter with single base pair changes in the forkhead binding sites
(AAACA /AGACA) at positions −1795, −1790, and −1784. For the MafA
promoter studies, we cloned a DNA fragment encompassing nt −8118 to
−7748 of the mouse MafA promoter (Zhao et al., 2005) into pGL3 basic and
performed cotransfection assays as indicated for NeuroD.
Chromatin immunoprecipitation assays
We performed ChIP assay in hepatocytes or βTC-3 cells following pre-
viously described methods (Nakae et al., 2003). For the NeuroD promoter,
we used the following primers: 5#-GCAGCAAAGCATGAACATTCA-3# and
5#-ACTGGCTGAGAGCAGAGCAAGCAAG-3# (−2119 w −2099 and −1743 w
−1717 of the mouse NeuroD promoter). For the MafA promoter, we used
the following primers: 5#-CACCCCAGCGAGGGCTGATTTAATT-3# and 5#-
AGCAAGCACTTCAGTGTGCTCAGTG-3# (−8118 to −8094 and −7772 to
−7748 of the mouse MafA promoter). All experiments were repeated at least
three times.
Immunofluorescence
We performed immunostaining with anti-FoxO1 (1:30), anti-NeuroD (1:100),
or anti-Ki67 (1:1000) antibodies as described (Kitamura et al., 2002). For
colocalization experiments with FoxO1 and Pml, we transfected FLAG-
tagged Pml and co-stained with anti-Flag (1:1,000) and anti-Cbp (1:30) anti-
bodies. For immunohistochemistry, we used 5 m-thick paraffin sections
and performed immunofluorescence as described previously (Kitamura et
al., 2002). In some experiments, we performed antigen retrieval before incu-
bation of primary antibodies. We used anti-insulin, anti-glucagon, anti-
FoxO1, anti-MafA, and anti-Sirt1 antibodies at dilutions of 1:2,000, 1:2,000,161
A R T I C L E1:30, 1:500, and 1:100, respectively. We visualized the immune complex
with FITC- or CY3-conjugated secondary antibodies.
Premature senescence
We isolated islets from 2-month-old C57/B6 mice and cultured them as
described previously (Kitamura et al., 2002). Five days after isolation, adher-
ent cells organized as monolayers. At this point, we treated the cells with
50 M H2O2 or low amount of adenovirus expressing FoxO1-ADA, FoxO1-
DN, or GFP (MOI = 1), then cultured the cells for 7 days in normal culture
medium. To measure premature senescence, we fixed and stained cells for
SA β-galactosidase activity as described (Dimri et al., 1995).
Mouse models
The following strains of mice have been described in previous publications:
Irs2−/− develop diabetes as a result of decreased β cell mass (Withers et
al., 1998). FoxO305 and FoxO307 develop diabetes secondary to increased
expression of hepatic glucogenetic genes, Pck1 and G6pc (Nakae et al.,
2002). Insulin receptor transgenic knockouts express insulin receptors ex-
clusively in liver, β cells and brain (L1) or liver and β cell (L2); as a result, L1
mice are insulin resistant but not diabetic, while L2 are insulin resistant and
diabetic (Okamoto et al., 2004). Insulin receptor mosaics (80) carry a mo-
saic deletion of Insulin receptor in w80% of somatic cells and are growth
retarded and hypoglycemic (Kitamura et al., 2004). We obtained L1 × 305
mice by intercrosses of FoxO305 and Insulin receptor transgenic knockouts
L1. We performed PCR genotyping as described.
Supplemental data
Supplemental data include five figures and can be found with this article
online at http://www.cellmetabolism.org/cgi/content/full/2/3/153/DC1/.
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